CollPlant Biotechnologies Reports Year End Financial Results for Fiscal Year 2020
CollPlant (NASDAQ: CLGN) announced its financial results for the year ended December 31, 2020, revealing significant growth with revenues of $6.1 million, a 165% increase from $2.3 million in 2019. The company entered a strategic agreement worth up to $103 million with Allergan Aesthetics, which included an upfront payment of $14 million. Despite an operating loss of $5.6 million, a 36% decrease from the previous year, CollPlant ended the year with $49 million in cash reserves. The company's ongoing innovations include developing 3D bioprinted breast implants.
- Revenues increased by 165% to $6.1 million, driven by licensing agreements.
- Strategic agreement with Allergan Aesthetics potentially worth $103 million.
- Operating loss decreased by 36% to $5.6 million.
- Cash reserves of $49 million as of March 2021.
- Operating costs increased by 7% to $8.7 million.
- Accretion of $1.9 million in non-cash charges impacted financial results.
REHOVOT, Israel, March 26, 2021 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced financial results for the full year ended December 31, 2020 and provided an update on the Company's business developments. Certain metrics, including those expressed on an adjusted basis, are non-GAAP measures. See "Use of Non-GAAP Measures" below.
"2020 and the beginning of 2021 were transformational for CollPlant as we continued to grow and strengthen our position in the global market with our regenerative rhCollagen-based technologies in both 3D printing and medical aesthetics," stated Yehiel Tal, Chief Executive Officer of CollPlant.
"We entered into a new development and commercialization agreement with Allergan Aesthetics, an AbbVie company, which came with substantial upfront and future milestone payments. Through this high-value collaboration, we are creating a paradigm shift in the medical aesthetics field by providing next-generation regenerative products with long lasting results."
"Our rhCollagen and BioInks are used today in the development of a broad range of 3D bioprinting applications conducted at CollPlant. We are particularly excited about the potential of our program for 3D bioprinted breast implants, which harness the potential to transform the field of breast reconstruction and augmentation."
"We recently established a platform for collaboration with 3D Systems in the field of 3D bioprinting to jointly address the need for a comprehensive solution to produce tissues and scaffolds for regenerative medicine applications," Mr. Tal concluded.
Full Year 2020 and Recent Highlights
rhCollagen Platform Technology Highlights
- Entered strategic agreement potentially worth
$103 million plus royalties and transfer pricing with Allergan Aesthetics, an AbbVie company, for rhCollagen in the use of dermal and soft tissue filler products. Received$14 million upfront. - Development of proprietary rhCollagen-based regenerative breast implants designed to gradually degrade and be replaced by newly grown natural breast tissue, and conducting preclinical study.
- Developing photocurable dermal/soft tissue filler formulation based on rhCollagen for the medical aesthetics market.
- Entered product manufacturing and supply agreement with STEMCELL Technologies, Canada's largest privately owned biotechnology company, for rhCollagen to be included in cell culture kits sold to scientists worldwide working in the stem cell, immunology, cancer, regenerative medicine, and cellular therapy research fields.
- Joined forces with 3D Systems to facilitate the development of 3D bioprinted tissues and scaffolds for regenerative medicine applications.
- Signed distribution agreements for Vergenix™ Flowable Gel product in Commonwealth of Independent States (CIS) countries: Belarus, Kazakhstan, Georgia, Azerbaijan, Armenia, Uzbekistan, and secured first substantial orders totaling hundreds of thousands of U.S. dollars.
- Licensing agreement terminated between CollPlant and United Therapeutics for bioprinting of scaffolds for lung transplants.
Corporate Highlights
- Raised
$39.45 million through a combination of$4.45 million in a private placement in February 2020 and a registered direct offering of$35 million in February 2021. - Appointed Roger Pomerantz, M.D., F.A.C.P., a well-respected life science industry expert and leader as Chairman of CollPlant's Board of Directors.
$49 million cash reserves including$14 million received from AbbVie as of March 2021.
Financial Highlights for the Full Year Ended December 31, 2020:
- CollPlant reported revenues of
$6.1 million for the full year 2020, a165% increase or$3.8 million compared to$2.3 million in the year 2019. The increase was primarily related to revenue recognized with respect to the kidney option exercised under the United license agreement. - Revenues from BioInk and sales of goods increased by
9% to$2.5 million in 2020, from$2.3 million in 2019. - Operating loss for the year 2020 was
$5.6 million , a decrease of36% compared to$7.6 million in the year 2019. - Comprehensive loss for the year 2020 was
$5.8 million , or$0.84 per share on a GAAP basis, or adjusted comprehensive loss of$3.9 million or$0.57 per share, on a non-GAAP basis. The year 2020 was negatively impacted by an accretion of a$1.9 million non-cash charges relating to the change in value of financial instruments, share based compensation and in operating lease accounts. - The Company ended the year 2020 with
$3.3 million in cash and cash equivalents. In addition, in February 2021, the Company raised$35 million against issuance of shares at$17.50 price per share and received$14 million upfront from AbbVie.
Year ended December 31, 2020 Financial Results on US GAAP basis ("GAAP")
Revenues for the year ended December 31, 2020 increased by
Total operating costs and expenses for the year ended December 31, 2020 increased by
Financial expense, net for the year 2020 was
Comprehensive loss for the year ended December 31, 2020 was
Cash used in operating activities during the year ended December 31, 2020, was
Cash used in investing activities during the year ended December 31, 2020, was
Cash provided by financing activities during the year 2020, was
Year ended 2020 Financial Results on Non-GAAP Basis
On a non-GAAP basis, the operating costs and expenses for the year 2020 increased by
The table on page 13 includes a reconciliation of the Company's GAAP results to non-GAAP results. The reconciliation reflects non-cash net expense in the amount of
Use of Non-GAAP Measures
This press release contains certain non-GAAP financial measures for operating costs and expenses, operating loss, comprehensive loss and basic and diluted comprehensive loss per share that exclude the effects of non-cash expense for fair market value attributed to services received through the share purchase agreement, change in fair value of financial instruments, share-based compensation to employees, directors and consultants, and change in operating lease accounts. Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the Company's performance that enhances management's and investors' ability to evaluate the Company's operating costs, comprehensive loss and loss per share, and to compare them to historical Company results.
The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when operating and evaluating the Company's business internally and therefore decided to make these non-GAAP adjustments available to investors. The non-GAAP financial measures used by the Company in this press release may be different from the measures used by other companies.
For more information on the non-GAAP financial measures, please see the "Reconciliation of GAAP to Non-GAAP Financial Measures" table on page 13 in this press release. This accompanying table on page 13 has more details on the GAAP financial measures that are most directly comparable to non-GAAP financial measures and the related reconciliations between these financial measures.
The Company's consolidated financial results as of, and for the year ended December 31, 2020 are presented in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP").
A copy of the Company's annual report on Form 20-F for the year ended December 31, 2020 has been filed with the U.S. Securities and Exchange Commission at www.sec.gov and posted on the Company's investor relations website at http://ir.collplant.com/. The Company will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request to CollPlant Investor Relations at 4 Oppenheimer, Weizmann Science Park, Rehovot 767104, Israel or by phone at +972-73-232 5600.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. CollPlant recently entered a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information, visit http://www.collplant.com.
Safe Harbor Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the impact of the COVID-19 pandemic; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk and products for medical aesthetics; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact at CollPlant:
Eran Rotem
Deputy CEO & Chief Financial Officer
Tel: + 972-73-2325600
Email: Eran@collplant.com
COLLPLANT BIOTECHNOLOGIES LTD. | |||||||||
CONSOLIDATED BALANCE SHEETS | |||||||||
(U.S. dollars in thousands) | |||||||||
December 31, | |||||||||
2020 | 2019 | ||||||||
Assets | |||||||||
Current assets: | |||||||||
Cash and cash equivalents | $ | 3,333 | $ | 3,791 | |||||
Restricted deposit | 12 | 12 | |||||||
Trade receivables | 830 | 79 | |||||||
Other accounts receivable and prepaid expenses | 239 | 270 | |||||||
Inventory | 1,262 | 888 | |||||||
Total current assets | 5,676 | 5,040 | |||||||
Non-current assets: | |||||||||
Restricted deposit | 181 | 168 | |||||||
Operating lease right-of-use assets | 2,796 | 3,215 | |||||||
Property and equipment, net | 2,106 | 2,329 | |||||||
Intangible assets | 82 | - | |||||||
Total non-current assets | 5,165 | 5,712 | |||||||
Total assets | $ | 10,841 | $ | 10,752 | |||||
COLLPLANT BIOTECHNOLOGIES LTD. | ||||||||||
CONSOLIDATED BALANCE SHEETS | ||||||||||
(U.S. dollars in thousands, except share data) | ||||||||||
December 31, | ||||||||||
2020 | 2019 | |||||||||
Liabilities and shareholders' equity | ||||||||||
Current liabilities: | ||||||||||
Current maturity of loan | $ | - | $ | 24 | ||||||
Trade payables | 798 | 833 | ||||||||
Operating lease liabilities | 440 | 455 | ||||||||
Deferred revenues | 207 | 942 | ||||||||
Accrued liabilities and other | 1,943 | 1,203 | ||||||||
Total current liabilities | 3,388 | 3,457 | ||||||||
Non-current liabilities: | ||||||||||
Derivatives liability | 28 | 68 | ||||||||
Operating lease liabilities | 2,948 | 3,139 | ||||||||
Total non-current liabilities | 2,976 | 3,207 | ||||||||
Total liabilities | 6,364 | 6,664 | ||||||||
Shareholders' Equity: | ||||||||||
Ordinary shares, NIS 1.5 par value - authorized: 30,000,000 ordinary shares as of December | 2,933 | 2,368 | ||||||||
Additional paid in capital and warrants | 75,547 | 69,949 | ||||||||
Currency translation differences | (969) | (969) | ||||||||
Accumulated deficit | (73,034) | (67,260) | ||||||||
Total shareholders' equity | 4,477 | 4,088 | ||||||||
Total liabilities and shareholders' equity | $ | 10,841 | $ | 10,752 | ||||||
COLLPLANT BIOTECHNOLOGIES LTD. | |||||||||||||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | |||||||||||||
(U.S. dollars in thousands, except share and per share data) | |||||||||||||
Year ended December 31, | |||||||||||||
2020 | 2019 | 2018 | |||||||||||
Revenues | $ | 6,137 | $ | 2,318 | $ | 5,014 | |||||||
Cost of revenues | 3,002 | 1,879 | 1,659 | ||||||||||
Gross Profit | 3,135 | 439 | 3,355 | ||||||||||
Operating expenses: | |||||||||||||
Research and development, net | 4,065 | 4,414 | 3,877 | ||||||||||
General, administrative and marketing | 4,669 | 3,656 | 3,723 | ||||||||||
Total operating loss | 5,599 | 7,631 | 4,245 | ||||||||||
Financial expenses | 34 | 3,303 | 2,180 | ||||||||||
Financial income | 40 | - | - | ||||||||||
Exchange differences | 181 | 230 | (176) | ||||||||||
Financial expenses, net | 175 | 3,533 | 2,004 | ||||||||||
Loss for the period | $ | 5,774 | $ | 11,164 | $ | 6,249 | |||||||
Other comprehensive loss: | |||||||||||||
Currency translation differences | - | - | (557) | ||||||||||
Total comprehensive loss for the period | 5,774 | 11,164 | 6,806 | ||||||||||
Basic and diluted loss per ordinary share | 0.84 | 2.23 | 1.43 | ||||||||||
Weighted average number of shares outstanding used in | 6,886,955 | 4,986,381 | 4,384,585 | ||||||||||
COLLPLANT BIOTECHNOLOGIES LTD. | ||||||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||
(U.S. dollars in thousands) | ||||||||||||
Year ended December 31, | ||||||||||||
2020 | 2019 | 2018 | ||||||||||
Cash flows from operating activities: | ||||||||||||
Net cash used in operations (see Appendix A) | $ | (4,451) | $ | (5,703) | $ | (1,217) | ||||||
Net cash used in operating activities | (4,451) | (5,703) | (1,217) | |||||||||
Cash flows from investing activities: | ||||||||||||
Purchase of intangible assets | (82) | - | - | |||||||||
Purchase of property and equipment | (437) | (1,491) | (832) | |||||||||
Proceeds from sale of property and equipment | - | 30 | - | |||||||||
Net cash used in investing activities | (519) | (1,461) | (832) | |||||||||
Cash flows from financing activities: | ||||||||||||
Proceeds from issuance of shares, warrants and debentures, less issuance expenses | 4,400 | 5,440 | 2,777 | |||||||||
Exercise of options into shares | 89 | 7 | - | |||||||||
Loan received | - | - | 58 | |||||||||
Loan repaid | (24) | (20) | (12) | |||||||||
Payments made for equipment on financing terms | - | (17) | (70) | |||||||||
Net cash provided by financing activities | 4,465 | 5,410 | 2,753 | |||||||||
Increase (Decrease) in cash and cash equivalents and restricted deposits | (505) | (1,754) | 704 | |||||||||
Cash and cash equivalents and restricted deposits at the beginning of the year | 3,971 | 5,663 | 5,284 | |||||||||
Exchange differences on cash and cash equivalents and restricted deposits | 60 | (62) | (325) | |||||||||
Cash and cash equivalents and restricted deposits at the end of the year | $ | 3,526 | $ | 3,971 | $ | 5,663 | ||||||
COLLPLANT BIOTECHNOLOGIES LTD. | ||||||||||||
APPENDICES TO THE CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||
(U.S. dollars in thousands) | ||||||||||||
Year ended December 31, | ||||||||||||
2020 | 2019 | 2018 | ||||||||||
Appendix to the statement of cash flows | ||||||||||||
A. Net cash used in operations: | ||||||||||||
Loss | $ | (5,774) | $ | (11,164) | $ | (6,249) | ||||||
Adjustments for: | ||||||||||||
Depreciation and amortization | 660 | 539 | 342 | |||||||||
Share-based compensation to employees and consultants | 1,674 | 1,125 | 1,434 | |||||||||
Exchange differences on cash and cash equivalents | (60) | (62) | (184) | |||||||||
Financial expenses (income) related to financial instruments | (40) | 3,230 | 2,293 | |||||||||
Net change of operating lease accounts | 213 | 382 | - | |||||||||
(3,327) | (5,950) | (2,364) | ||||||||||
Changes in operating asset and liability items: | ||||||||||||
Decrease (increase) in trade receivables | (751) | 437 | (439) | |||||||||
Increase in inventory | (374) | (74) | (653) | |||||||||
Decrease in other receivables | 31 | 35 | 220 | |||||||||
Increase (decrease) in trade payables | (35) | 228 | (112) | |||||||||
Increase in accrued liabilities and other payables | 740 | 629 | 99 | |||||||||
Increase (decrease) in deferred revenues (including long term deferred revenues) | (735) | (1,008) | 2,032 | |||||||||
(1,124) | 247 | (1,147) | ||||||||||
Net cash used in operations | $ | (4,451) | $ | (5,703) | $ | (1,217) | ||||||
B. Supplementary information on investing and financing activities not involving | ||||||||||||
Conversion of debentures to pre-paid warrants | - | - | 3,267 | |||||||||
Conversion of pre-paid warrants to ordinary shares | 355 | 22 | 68 | |||||||||
Obtaining right of use assets in exchange for a lease liability | 23 | 97 | - | |||||||||
Exercise of anti-dilution derivatives | - | 2,024 | - | |||||||||
Classification of warrants from liabilities to equity, net | - | 1,335 | - | |||||||||
C. Reconciliation of Cash, cash equivalents and restricted cash at the end of the | ||||||||||||
Cash and cash equivalents | 3,333 | 3,791 | 5,354 | |||||||||
Restricted deposits (including long term) | 193 | 180 | 154 | |||||||||
Total cash and cash equivalents and restricted deposits | $ | 3,526 | $ | 3,971 | $ | 5,663 | ||||||
CollPlant Biotechnologies Ltd. | ||||||||
Reconciliation of GAAP to Non-GAAP Financial Measures | ||||||||
(Unaudited) | ||||||||
Year ended December 31, | ||||||||
2020 | 2019 | |||||||
USD in thousands | ||||||||
GAAP gross profit | $ | 3,135 | $ | 439 | ||||
GAAP operating costs and expenses: | 8,734 | 8,070 | ||||||
Change of operating lease accounts | (213) | (382) | ||||||
Share-based compensation to employees, directors and consultants | (1,674) | (1,125) | ||||||
Non-GAAP operating costs and expenses: | 6,847 | 6,563 | ||||||
GAAP operating loss | 5,599 | 7,631 | ||||||
Non-GAAP operating loss | 3,712 | 6,124 | ||||||
GAAP Comprehensive loss | 5,774 | 11,164 | ||||||
Change in fair value of financial instruments | 40 | (3,230) | ||||||
Change of operating lease accounts | (213) | (382) | ||||||
Share-based compensation to employees, directors and consultants | (1,674) | (1,125) | ||||||
Non-GAAP Comprehensive loss | $ | 3,927 | $ | 6,427 | ||||
GAAP Basic and diluted loss per ordinary share | $ | 0.84 | $ | 2.23 | ||||
Non-GAAP Basic and diluted loss per ordinary share | $ | 0.57 | $ | 1.29 | ||||
View original content to download multimedia:http://www.prnewswire.com/news-releases/collplant-biotechnologies-reports-year-end-financial-results-for-fiscal-year-2020-301256696.html
SOURCE CollPlant
FAQ
What were CollPlant's revenue results for 2020?
What is the significance of the agreement with Allergan Aesthetics for CLGN?
What were the main financial losses reported by CollPlant in 2020?
What are the future prospects for CollPlant's products?
